Board & Management team

Dimerix has a highly experienced board and management team made up of individuals who have successfully commercialised pharmaceutical products globally. This team is responsible for the strategic direction, operations and success of the Company.

Mark Diamond BSc, MBA

Non-Executive Chairman

View full biography

View
CLOSE
Mark Diamond BSc, MBA

Mark Diamond BSc, MBA

Non-Executive Chairman

Mr Mark Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries. In May 2023, Mr Diamond retired from ASX listed Antisense Therapeutics Limited as Managing Director and CEO, a position he had held since 2001, making him at the time of his retirement the longest serving CEO of a publicly traded Healthcare Company on the ASX. At Antisense, Mr Diamond was responsible for capital market engagement, pipeline development, product out-licensing and clinical trial conduct among other significant accomplishments. In 2022, Mr. Diamond was the recipient of The Biotech Daily CEO of the Year award. Prior to his time at Antisense, Mr Diamond served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations.

Mr Diamond holds a Bachelor of Science degree from Monash University and an MBA from Macquarie University.

 

Nina Webster, PhD, M IP Law, MBA

Chief Executive Officer / Managing Director

View full biography

View
CLOSE
Nina Webster, PhD, M IP Law, MBA

Nina Webster, PhD, M IP Law, MBA

Chief Executive Officer / Managing Director

Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina is also a Non-Executive Director for Linear Clinical Research Limited. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT.

Hugh Alsop, BSc (Hons), MBA

Non-Executive Director

View full biography

View
CLOSE
Hugh Alsop, BSc (Hons), MBA

Hugh Alsop, BSc (Hons), MBA

Non-Executive Director

Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. Hugh has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has a track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.

Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, where he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that licensed the testosterone product Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.

Clinton Snow, BEng (Hons), BCom 

Non-Executive Director

View full biography

View
CLOSE
Clinton Snow, BEng (Hons), BCom 

Clinton Snow, BEng (Hons), BCom 

Non-Executive Director

Clinton Snow has nearly 20 years experience as a technology leader with a focus in engineering management, project delivery, risk management, and assurance. Clinton is currently a non-executive director for Icetana Ltd (ASX:ICE) and provides advisory services to a family office with multiple Australian biotech investments.

Clinton holds a Bachelor of Chemical Engineering (honours) and Bachelor of Commerce degree from The University of Melbourne.

Sonia Poli, PhD

Non-Executive Director

View full biography

View
CLOSE
Sonia Poli, PhD

Sonia Poli, PhD

Non-Executive Director

Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Sonia has held various corporate responsibilities such as outsourcing and out-licensing, and she has promoted academic collaborations and supported R&D collaborations with external partners.

Sonia is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas.

Sonia is co-author of more than 50 scientific papers and several patents. Sonia holds a Masters degree and a PhD in industrial chemistry from Milan University (IT).

Hamish George, BCom, CA, GIA(Cert)

Chief Financial Officer / Company Secretary

View full biography

View
CLOSE
Hamish George, BCom, CA, GIA(Cert)

Hamish George, BCom, CA, GIA(Cert)

Chief Financial Officer / Company Secretary

Hamish has experience in providing financial advice and CFO services to businesses ranging from small start-ups to large established businesses with turnover of over $50 million. He brings expertise in areas including financial/management reporting, Company Secretarial, cash flow management, taxation including (R&D Tax Incentive), Company Establishments, company valuations, budgeting and forecasting. Hamish is also a member of the senior management team at Bio101, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

David Fuller, B.Pharm (Hons), MBBS

Chief Medical Officer

View full biography

View
CLOSE
David Fuller, B.Pharm (Hons), MBBS

David Fuller, B.Pharm (Hons), MBBS

Chief Medical Officer

David is an internationally experienced pharmaceutical executive and physician, with over 35 years of international experience in drug development and commercialisation. David has a strong background product development, as well as a successful history of securing multiple INDs/NDAs (or equivalent) with both the FDA and EMA. He has led teams that successfully obtained major market product approvals for Renagel (chronic kidney disease, EU, including post-approval support) Moraxen (cancer pain, UK), Busulfex (haematologic oncology; US Paediatrics and EU Adult indications), Xyrem (narcolepsy; US).

David has extensive experience in product development and commercialization, from Planning, Financing, Pre-clinical, Clinical Development, Regulatory Approval, Product Launch, Pharmacovigilance, and Medical Affairs. He has designed and executed multiple GCP Phase 1-3 studies across the US, EU, and Asia for both orphan and major market products.

David has a proven track record of creating value across private and ASX listed large and small-cap environments. David was the former CMO of Race Oncology,  and is also a Non-Executive Director at AdAlta Limited and EpiAxis Therapeutics Pty Ltd. David holds Bachelor of Medicine/Bachelor of Surgery and Bachelor of Pharmacy degrees from University of Sydney.

Robert Shepherd, PhD, MBA

Chief Commercialisation Officer

View full biography

View
CLOSE
Robert Shepherd, PhD, MBA

Robert Shepherd, PhD, MBA

Chief Commercialisation Officer

Robert is an experienced pharmaceutical executive having lead multidisciplinary research and development teams for over 11 years. Prior to joining the Dimerix team, Robert was a Senior Development Manager at Medicines Development for Global Health, a non-profit organisation focused on efficiently developing drugs for orphan and neglected indications. In this role, he supported biotechnology and academic groups in project management roles spanning research, manufacturing, nonclinical, clinical and regulatory fields in pain, immunology, infectious diseases, and oncology. Robert has previously held roles as a Business Analyst at the Monash Vision Group, Communications Advisor at the Australian Society of Plant Scientists, and Sessional Lecturer at Monash University. Robert holds a BS in Genetics (Honours), PhD in molecular cell biology and immunology, an MBA and a graduate certificate in science commercialisation from Monash University, Australia.

Bronwyn Pollock, BSc (Hons), MBA

Vice President Product Development

View full biography

View
CLOSE
Bronwyn Pollock, BSc (Hons), MBA

Bronwyn Pollock, BSc (Hons), MBA

Vice President Product Development

Bronwyn Pollock is an experienced biotech and pharmaceutical professional with over 20 years in the industry. Prior to leading the Product Development work at Dimerix, Bronwyn was Director of Product Development at Prota Therapeutics. She has also held Senior Management positions in pharmaceutical companies including Neuren Pharmaceuticals Ltd, Hospira Australia (now Pfizer), Acrux Ltd and CSL. Her CMC (Chemistry, Manufacturing and Controls) experience comes from working in R&D, quality and program management, and she has been involved in leading teams in the development and submission of numerous dossiers to EMA, US FDA, Asia and Sth America, technology transfers and launch.

We use our innovative receptor technology in order to uncover pharmaceutical products that will improve patient’s lives.